Johnson & Johnson

EQS-News: Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada

Retrieved on: 
Wednesday, April 10, 2024
Ulcerative colitis, Psoriasis, Ustekinumab, Patient, EMA, Interleukin, European Medicines Agency, Fresenius (company), Cytokine, Johnson & Johnson, FDA, Food, Pharmaceutical industry

Press release // March 18, 2024

Key Points: 
  • Press release // March 18, 2024
    Munich, Germany – Formycon AG (FSE: FYB) and its commercialization partner Fresenius Kabi today announced the signing of a settlement agreement with Johnson & Johnson concerning the commercialization of FYB202, a biosimilar to Stelara®1 (ustekinumab), in Europe and Canada.
  • It was agreed to keep the terms of the agreement confidential.
  • Our aim is to make a significant difference in patients' lives by providing them with reliable, high-quality, and affordable treatment options.
  • In February 2023, Formycon and Fresenius Kabi had entered into a global license agreement for the ustekinumab biosimilar candidate FYB202, under which FYB202 will be marketed by Fresenius Kabi in key global markets following successful approval.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, MODN, ABIO

Retrieved on: 
Monday, April 8, 2024
ARCA, Model N, Shock wave, Sale, Aimco, Fraud, Johnson & Johnson, Vista Equity Partners, Advertising, Security (finance)

If you are a Shockwave shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Shockwave shareholder, click here to learn more about your rights and options .
  • If you are an Apartment Income shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN), ARCA biopharma, Inc. (Nasdaq - ABIO)

Retrieved on: 
Monday, April 8, 2024
ARCA, Model N, JNJ, Brodsky, Johnson & Johnson, Vista Equity Partners, Model, AIR, Vista, Security (finance)

BALA CYNWYD, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the Merger Agreement, Shockwave will be acquired by Johnson & Johnson (NYSE - JNJ).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

Retrieved on: 
Monday, April 8, 2024
Shingles, Editas Medicine, Regulatory affairs, Bristol Myers Squibb, Doctor of Philosophy, MBA, Rutgers University, Immunization, Johnson & Johnson, Allergan, RAC, Vaccine, Purdue University, Pharmaceutical industry

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved tolerability and accessibility, today announced Dr. Chi Li is joining as the company’s Chief Regulatory Officer responsible for the global regulatory strategy for amezosvatein.

Key Points: 
  • SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved tolerability and accessibility, today announced Dr. Chi Li is joining as the company’s Chief Regulatory Officer responsible for the global regulatory strategy for amezosvatein.
  • “We are thrilled to have Dr. Li join the Curevo team and build upon the regulatory progress made thus far,” stated George Simeon, Curevo’s Chief Executive Officer.” Dr. Li will play a key role in finalizing our global regulatory strategy and harmonizing our approach to key entry markets in Europe, the USA, China, Japan, and other important markets for our shingles and varicella vaccine.”
    Dr. Li’s impressive 20+ year career in regulatory affairs features multiple regulatory successes globally.
  • “I’m genuinely impressed at what the Curevo team has accomplished to date and am excited to join such a dynamic group,” said Dr. Li.
  • Previously, Dr. Li served as Vice President, Regulatory Affairs at both Allergan and Bayer.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, KTRA, ABIO

Retrieved on: 
Friday, April 5, 2024
Advertising, Shock wave, ARCA, Sale, Therapy, Fraud, Johnson & Johnson, Security (finance)

If you are a Shockwave shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Shockwave shareholder, click here to learn more about your rights and options .
  • If you are a Kintara shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

CURE Media Group and Oncology Nursing News announce Kristen Dahlgren as keynote speaker for the 2024 Extraordinary Healer® event

Retrieved on: 
Friday, April 5, 2024
Washington Convention Center, Congress, Caregiver, Walter, Patient, Research, News, Cancer, University, Woman, Survivor, Johnson & Johnson, Breast cancer, Immune system, Media Group, Multimedia, Vaccine, CURE, Young, PEP, Courage

This award honors oncology nurses whose compassion and expertise improve the lives of their patients.

Key Points: 
  • This award honors oncology nurses whose compassion and expertise improve the lives of their patients.
  • “We are honored to have Kristen Dahlgren as our keynote speaker for the 2024 Extraordinary Healer recognition program,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences®, the parent company of CURE.
  • For the first 30 years of her career, Dahlgren traveled the world where she actively worked on documenting some of the biggest news stories.
  • For more information on the 2024 Extraordinary Healer event and to register, please visit the event page .

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, AstraZeneca, Merck, Cancer, Doctor of Philosophy, Spacecraft, B7-H4, Antibody, Johnson & Johnson, Immunotoxin, CSO, MedImmune

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.

Key Points: 
  • BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.
  • As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4.
  • “We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug conjugates,” said Solomon Langermann, PhD, NextCure’s chief scientific officer.
  • “Rakesh is a world authority on ADCs and has an incredible record of researching and developing them.

Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer

Retrieved on: 
Monday, April 1, 2024
Burn, Brigham Young University, Avita Medical, MDAI, Business administration, Patient, Global strategy, Artificial intelligence, Spectral, Publication, Master of Business Administration, Health Economics, Johnson & Johnson, Allergan, Government, Physician, Medtech

DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer.

Key Points: 
  • DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer.
  • Jeremiah has more than 20 years of medical device marketing experience, including global marketing and business strategy.
  • Mr. Sparks will be responsible for both domestic and international product commercialization.
  • “We are thrilled to have Jeremiah join the company as we move towards commercialization of DeepView,” said Peter M. Carlson, CEO of Spectral AI.

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Retrieved on: 
Thursday, March 28, 2024
Patient, Chairperson, CNS, Mental health, Innovation, CMPS, Psilocybin, TRD, Johnson & Johnson, Operation, Pain, KCL, Frustration, J&J, Food, Nursing

David Norton, lead independent director on the Compass board of directors, will become interim chair.

Key Points: 
  • David Norton, lead independent director on the Compass board of directors, will become interim chair.
  • Compass is running a global search for a permanent board chair, focused on recruiting a leader with a strong background in the biotechnology sector and broad strategic experience across the product lifecycle.
  • “When we started Compass eight years ago, we could not have imagined how the company would grow and mature,” said George Goldsmith, outgoing board chair of Compass Pathways.
  • He has been a member of the Compass board of directors since 2018, serving as lead independent director.

LogiPharma 2024 Playbook Highlights Why Real-Time Visibility & Data are Critical to Ensuring the Quality & Safety of New Medicines & Patient Therapies

Retrieved on: 
Tuesday, March 26, 2024
Automation, Temperature, Agility, Risk management, Research, Cold chain, Playbook, Johnson & Johnson, Artificial intelligence, Medtech, Fine chemical

The Playbook includes a detailed examination by Alex Guillen, Tive's Global SME in Life Sciences and Pharma, on the role of precise and timely supply chain data.

Key Points: 
  • The Playbook includes a detailed examination by Alex Guillen, Tive's Global SME in Life Sciences and Pharma, on the role of precise and timely supply chain data.
  • Guillen believes that ensuring the successful delivery and launch of dozens of new cell and gene therapies, as expected in 2024, is fundamentally dependent on the industry’s advancements in real-time supply chain visibility.
  • “An essential part of the conversation for pharma leaders today is how to address the critical challenges of modern therapy delivery," said Guillen.
  • To learn more about Tive and LogiPharma 2024, please visit www.tive.com and www.logipharmaeu.com .